{"filing":{"accession_number":"0001193125-26-342321","cik":"0002056611","ticker":null,"company_name":"Latigo Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d170764d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2056611/000119312526342321/d170764d8k.htm"},"events":[{"id":26507,"run_id":24094,"accession_number":"0001193125-26-342321","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"The Company amended its certificate of incorporation and bylaws in connection with the IPO closing on August 10, 2026. These routine governance document updates were previously approved by the Board and stockholders and became effective upon IPO closing.","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27657,"accession_number":"0001193125-26-342321","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws in connection with the IPO closing on August 10, 2026. While the IPO itself is a material event, the Item 5.03 filing addresses only the administrative governance documents (Restated Certificate and Restated Bylaws) that were previously approved by the Board and stockholders and became effective upon IPO closing. These are standard corporate governance housekeeping items that do not themselves constitute a material event to investors beyond the IPO transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:42.420025+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":26508,"run_id":24094,"accession_number":"0001193125-26-342321","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Latigo Biotherapeutics completed its initial public offering on August 10, 2026, generating $345.6 million in gross proceeds through the issuance of equity securities.","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27658,"accession_number":"0001193125-26-342321","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"The disclosure describes completion of an IPO generating $345.6 million in gross proceeds. While this is clearly a material capital-raising event, it does not fit neatly into the provided taxonomy. \"Debt_issuance\" is the closest available category as it covers creation of direct financial obligations and capital-raising events, though an IPO is technically an equity issuance rather than debt. The event is material and must be classified despite the imperfect fit.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:42.420025+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27657,"accession_number":"0001193125-26-342321","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure concerns routine amendments to the Company's certificate of incorporation and bylaws in connection with the IPO closing on August 10, 2026. While the IPO itself is a material event, the Item 5.03 filing addresses only the administrative governance documents (Restated Certificate and Restated Bylaws) that were previously approved by the Board and stockholders and became effective upon IPO closing. These are standard corporate governance housekeeping items that do not themselves constitute a material event to investors beyond the IPO transaction itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:42.420025+00:00","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-08-10"},{"id":27658,"accession_number":"0001193125-26-342321","item_number":"8.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.25,"reasoning":"The disclosure describes completion of an IPO generating $345.6 million in gross proceeds. While this is clearly a material capital-raising event, it does not fit neatly into the provided taxonomy. \"Debt_issuance\" is the closest available category as it covers creation of direct financial obligations and capital-raising events, though an IPO is technically an equity issuance rather than debt. The event is material and must be classified despite the imperfect fit.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:42.420025+00:00","company_name":"Latigo Biotherapeutics, Inc.","ticker":null,"filing_date":"2026-08-10"}]}